Eli Lilly loses patent lawsuit for Strattera
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
Legal Issues Eli Lilly and Co. Public Companies Patent Generic drugs Health Care & Insurance Health Care & Life Sciences Pharmaceutical Law